rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Theriva Biologics, Inc.

TOVX · NYSE American

Health CareBiotechnologyNot moving yet

TOVX stood above a rising 150-day average in 3 of the last 52 weekly readings, and has been out of that trend for the last 5 weeks. It is 17.9% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 5
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
23 (+4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 3 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders23+4 on the quarter
New · exited6 · 2
Reported value$474K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026486,179$122K+293,775+152.7%
JANE STREET GROUP, LLCadded · filed 14 Aug 2026331,922$83K+154,888+87.5%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026294,021$74K-156,242−34.7%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 2026241,780$60K00.0%
Ikarian Capital, LLCunchanged · filed 14 Aug 2026112,076$28K00.0%
NORTHERN TRUST CORPnew · filed 13 Aug 202682,700$21K+82,700
RENAISSANCE TECHNOLOGIES LLCnew · filed 13 Aug 202663,710$16K+63,710
UBS Group AGreduced · filed 13 Aug 202661,053$15K-164,571−72.9%
XTX Topco Ltdreduced · filed 14 Aug 202653,868$13K-40,752−43.1%
Ground Swell Capital, LLCnew · filed 5 Aug 202635,292$8,830+35,292
30 Sep 2024 – 30 Jun 2026
101723Sep 24Mar 25Sep 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Jeffrey Alan Wolf Company insiderDirector · last 5 Jan 20260 · 0
Jeffrey J. Kraws Company insiderDirector · last 5 Jan 20260 · 0
John J. Monahan Company insiderDirector · last 5 Jan 20260 · 0
Steven A. Shallcross Company insiderCEO and CFO · last 5 Jan 20269 · 0
Francis Tufaro Company insiderChief Operating Officer · last 15 Dec 20220 · 0
Scott Tarriff Company insiderDirector · last 4 Dec 20190 · 0
Intrexon Corp Company insider10% owner · last 3 Apr 20191 · 3
Joseph A. Sliman Company insiderChief Medical Officer · last 20 Dec 20170 · 0
Jeffrey Scott Riley Company insiderChief Executive Officer · last 30 Nov 20164 · 0
Randal J. Kirk Company insider10% owner · last 2 Sep 20152 · 0
Charles Evan Ballantyne Company insiderChief Financial Officer · last 8 Jan 20151 · 0
Steve H. Kanzer Company insiderTenPercentOwnerOther · last 30 Apr 201417 · 3

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-85.2%
Debt to equityFY 2025 · to 31 Dec 20250.11×
Share count trendFY 2025 · to 10 Mar 202628.6%
Cash and equivalentsFY 2025 · to 31 Dec 2025$13.1M
Free cash flowFY 2025 · to 31 Dec 2025−$16.7M

Analyst forecasts

No analyst forecasts yet.